Alzheimer’s

European Medicines Agency Deems Imaging Biomarker a Qualified Measure to Select Patients with Early Stages of Cognitive Impairment for Alzheimer’s Disease Clinical Trials

Based on a request for regulatory review by Critical Path Institute’s (C-Path) Coalition Against Major Diseases (CAMD), the

January 12, 2011

Patient Self-report for Evaluating Mild Cognitive Impairment and Prodromal Alzheimer’s Disease

Capturing the Signal in Mild Cognitive Impairment of the Alzheimer’s Type: Industry Partnerships in Pre-Competitive Measure Development

Measuring the Earliest Symptoms of Mild Cognitive Impairment

C-Path Joins Leading Voices and Organizations in Alzheimer’s Research, Drug Discovery and Care to Call for Dramatic New Strategy to Stop Alzheimer’s Disease in Report Out Today

Leaders Engaged on Alzheimer’s Disease (LEAD) was created in February 2008 as an open network of Alzheimer’s-serving o

Critical Path Institute and Clinical Data Interchange Standards Consortium Announce Release of Data Standards for Alzheimer’s Disease Research

Critical Path Institute(C-Path)and Clinical Data Interchange Standards Consortium(CDISC) today announced the release of version 1.

C-Path’s K. Romero Co-Authors Special Report- Striving for an Integrated Drug-Development Process for Neurodegeneration: the Coalition Against Major Diseases

Alzheimer’s and Parkinson’s diseases are the two main neurodegenerative disorders and despite the public health need,

Executive director of Critical Path Institute’s Coalition Against Major Diseases testifies before congress on Alzheimer’s disease progress

Marc Cantillon, MD, presents the critical role of public/private partnerships in creating innovative tools to advance the developm

Leading Neuroscientist Joins Critical Path Institute

Marc Cantillon, MD, has joined Critical Path Institute as Executive Director of one of its major consortia, the Coalition Against

Public Release of Alzheimer’s Clinical Trial Data by Pharmaceutical Researchers

Previous56 Next